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ABSTRACT 
Investigations into the use of baboons as organ donors for human transplant recipients, a procedure called 
xenotransplantation, have raised the specter of transmitting baboon viruses to humans and possibly estab-
lishing new human infectious diseases. Retrospective analysis of tissues from two human transplant recipients 
with end-stage hepatic disease who died 70 and 27 days after the transplantation of baboon livers revealed 
the presence of two simian retroviruses of baboon origin, simian foamy virus (SFV) and baboon endogenous 
virus (BaEV), in multiple tissue compartments. The presence of baboon mitochondrial DNA was also detected 
in these same tissues, suggesting that xenogeneic "passenger leukocytes" harboring latent or active viral in-
fections had migrated from the xenografts to distant sites within the human recipients. The persistence of SFV 
and BaEV in human recipients throughout the posttransplant period underscores the potential infectious risks 
associated with xenotransplantation. 
BABOONS HARBOR several exogenous retroviruses that exist as persistent, life-long infections.! Of these, simian T celllym-
photropic virus (STL V) induces lymphomas and leukemias, 
while others such as simian foamy virus (SFV) cause little or no 
apparent disease in baboons.2,3 SFV is infectious for humans, 
having been transmitted from nonhuman primates to humans at 
primate facilities in the United States and elsewhere.4 Baboons 
also carry a replication-competent endogenous retrovirus (BaEV) 
that is found at high copy number and distributed throughout the 
baboon genome and infects human cells in vitro.5 It is conceiv-
able that simian retroviruses may represent possible infectious 
disease risks in human transplant recipients. Previous studies 
have shown the existence of chimerism established in both allo-
geneic and xenogeneic transplant recipients in which lympho-
cytes from donor organs were found to circulate in the recipi-
ent.6,7 Although no infectious diseases have been apparent that 
could have been attributed to the transfer of a baboon virus to 
humans, there is the potential for migrating baboon cells to dis-
seminate simian viruses to the human recipients.! This stUdy 
was undertaken to determine if human xenotransplant recipients 
had evidence of simian retroviruses of possible public health 
concern. 
The first baboon-to-human liver transplant was attempted in 
June 1992 to an HIV-infected patient and the second was in 
January 1993; patient 2 was a 62-year-old male who also re-
ceived donor bone marrow intravenously and survived for 27 
days.7,s Both patients had hepatitis B virus (HBV)-associated 
cirrhosis and were HBV carriers. Patient 1 was a 35-year-old 
male who survived 70 days. Neither transplanted liver func-
tioned normally. In addition, both patients developed renal fail-
ure and multiple posttransplant infectious complications. Both 
patients received an immunosuppressive regimen of FK-506, 
prednisone, and cyclophosphamide. The two adult male ba-
boons were screened against a panel of simian and human 
viruses and were negative for STLV, SIV, and simian retro-
virus (SRV). 
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Since evidence of antiviral antibody responses generally cor-
responds with active infection, antibodies against SFV in donor 
baboons were assessed by Western blotting. lrnrnunoblot strips 
were prepared with gel-purified SFV viral proteins. The estab-
lished criterion used for SFV infection has been serologic re-
activity to the two gag-related proteins p74 and p70, which are 
highly immunogenic and have been shown to correlate directly 
with SFV infection.9 As seen in Fig. lA, anti-p74/p70 anti-
bodies were detected in samples from both donor baboons prior 
to transplantation whereas the human patients were nonreactive 
at several time points during the posttransplantation period; 
however, a faint p74 band was visible at day 22 (Fig. lB). The 
failure of patient 2 to generate a significant antiviral antibody 
response may have been due to the insufficient time between 
transplantation and death. For patient 1, HIV infection may have 
had a role in suppressing antiviral responses. In addition, the 
immunosuppressive regimens used to treat both recipients in-
hibit B and T cell responsiveness.1,8 
To assess directly the presence of SFV in tissues of these pa-
tients, DNA extracted from tissue specimens were subjected to 
polymerase chain reaction (PCR) amplification using a set of 
SFV primers specific to the R-V5 region of the long terminal re-
peat (L TR). This region is highly conserved and has been used 
to amplify SIV from a variety of African and Asian nonhuman 
primates.3,g The amplified products were further analyzed by 
Southern blotting using a 32P-labeled LTR probe to increase sen-
sitivity and as a means for confirming the identity of the ampli-
fied products. As seen in Fig. 2, an identifiable L TR band of ap-
proximately 329 bp was visible in multiple tissue samples from 
both human recipients. In patient 2, SFV DNA was detected in 
the liver graft on day 24 but not day 12. The liver sample taken 










FIG. 1. Immunoblot analysis of serum samples from donor 
baboons and human transplant recipients. Serum samples from 
the baboon donors (A) or human transplant recipients (B) were 
diluted 1:40 and reacted with SFV immunoblot strips. Positive 
and negative controls were used at a 1:80 dilution. Im-
munoblotting was performed as previously described with SFV-
Babl as the antigen.3 SFV-Babl used for making Western blot 
reagents was isolated from peripheral blood lymphocytes of a 
baboon that developed lymphoma and has been previously de-
scribed.3 Virus was grown in primary human foreskin fibrob-
lasts (HFSM) and harvested during the cytopathic phase of in-
fection. HSFM cells were grown in Dulbecco's modified 
Eagle's medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS), 2 mM L-glutamine, penicillin (50 Vlml), and 
streptomycin (50 J-Lg/ml). 
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FIG. 2. Detection of SFV DNA in tissues from human liver 
transplant patients. PCR amplification of SFV DNA using LTR 
primers was performed with DNA from (A) patient I and (B) 
patient 2. Designations are as follows: PBMC, peripheral blood 
mononuclear cells; LN, lymph node; LIV, liver, KID, kidney; 
BM, bone marrow; and GI, small intestine. PBMC DNA sam-
ples from an SFV -seronegative human and an SFV+ baboon were 
used as negative and positive controls, respectively. A total of 
100 ng of total cellular DNA was added to 200 J-LM dNTPs, 50 
mM KCl, 10 mM Tris, 2.5 mM MgCI2, bovine serum albumin 
(BSA, 5 mg/ml), 30 pmol of primer, and I V of Taq polymerase 
(Promega, Madison, WI). Amplification was performed using the 
following primers: PBFI (5' -CACT ACTCGCTGCGTCGA-
GAGGTGT-3') and PBF2 (5'-GGAATTTTGTATATTGAT-
TATCC-3'). A 329-bp fragment within the SFV LTR (nt 
786-1115, based on the HFV sequence) was amplified. Condi-
tions for LTR primers were as follows: 1 cycle at 94°C for I min, 
52°C for 45 sec and noc for 1 min; I cycle at 94°C for I min, 
50°C for 45 sec, and noc for I min; 1 cycle at 94°C for 1 min, 
48°C for 45 sec, and noc for 1 min; 1 cycle at 94°C for 1 min, 
46°C for 45 sec, and noc for 1 min; 25 cycles at 94°C for 1 
min, 45°C for 45 sec, aI\d noe for 1 min; followed by exten-
sion at noc for 7 min. Amplified fragments were separated on 
agarose gels, blotted onto Nytran Plus membranes, and then hy-
bridized with 32P-Iabeled SFV-Babl LTR probe. 
tected in both lymph node and kidney on day 70. It is possible 
that the levels of SFV in the liver of patient 2 were initially be-
low the detection limits of this assay, while the later positive sig-
nal resulted from an increase in the number of active or latently 
infected cells. Because the sizes of the baboon livers were small 
in comparison with the recipients and were found to regenerate 
within 3 weeks to the appropriate liver mass for those recipients, 
it is conceivable that this proliferative phase also allowed for 
replication of viruses or cell types that may have harbored SFV. 
This would account for the delayed presence in patient 2 of SFV 
DNA in the graft. To ensure the integrity of the DNA prepara-
tions in those samples that were SFV negative, we successfully 
amplified the ,B-globin gene from each sample (not shown). We 
also repeated PCR analysis of the tissue samples from both pa-
tients, and the only difference was a negative signal in the DNA 
sample taken from the small intestine. 
The life cycle of SFV includes integration of proviral DNA 
into the host genome. Our ability to amplify SFV may reflect 
TABLE 1. DETECfION OF BABOON-RELATED DNA IN HUMAN LIVER TRANSPLANT PATIENTS 
Sample SFV (LTR)a BaEV' Baboon mitochondrial DNAc 
Baboon PBMCs (positive control) +++/+++ ++ +++ 
Human PBMCs (negative control) -/-
Patient 1 
PBMCs (day 25) -/- + 
LN (day 11) -/- + + 
LN (day 70) +/+ ++ +++ 
Liver (day 16) -/- ++ +++ 
Kidney (day 70) +/+ + +++ 
Patient 2 
PBMCs (pretransplantation) -/-
PBMCs (day 25) -/-
LN (day 27) +/+ + +++ 
Liver (day 12) -/- ++ +++ 
Liver (day 27) +++/+++ ++ +++ 
Kidney (day 27) +/+ + + 
Bone marrow (day 27) +/- ++ ++ 
aSimian foamy virus LTR DNA was amplified on two different occasions with separate samples that 
had been stored in another laboratory. Signal intensity was scored from (+) weak to (+ + +) strong. 
bA 389-bp BaEV proviral fragment was amplified by PCR using pol primers BPOLF4 and BPOLRS. 
Amplification conditions included 40 cycles, with 1 min of denaturation (94°C), annealing (SO°C), and 
extension (72°C). Detection of the PCR product was made by Southern blot hybridization with the 
32P-labeled BaEV internal probe BPOLP3. The sequences of the primers and probe are as follows and 
are based on the GenBank accession number M16SS0: BPOLF4 (5'-AGAAAACCAACCAAGCCCA-
CACG-ATT-3'), BPOLR5 (S'-CAGCTTTGTTCTTGATTICCTTTCCTTCTGAG-3'), and BPOLP3 
(5'-GGGCACAATCACTACCTCCTGGCA-3'). 
cBaboon mitochondrial DNA was detected by amplifying a 312-bp fragment from the mitochondrial 
cytochrome oxidase subunit II (COIl) gene, using baboon-specific primers as previously described 10: 
BCOIIFI (5' -CACTAACATCACGGACGCCCAA-3') and BCOIIRI (5' -GCCTGGTCGTG-TGGCTG-
TAAATAC-3'). Products were electrophoresed on 1.5% agarose gels followed by Southern blotting 









FIG. 3_ Unrooted consensus tree of SFV-hu2 LTR DNA from human transplant recipient. The designations for foamy viruses 
are as follows: SFV-hu2(lnl), -hu2(ln3), -hu2(liv) (human recipient), SFV-l (macaque), SFV-3, -Agml (African green monkey), 
SFV-Babl, -Bab3 (baboon), SFV-Gg (gorilla), SFV-6, -7, and CPZ (chimpanzee), SFV-ll (orangutan), SFV-Pat (patas), and 
SFV-Hml (Hamlyn's guenon). LTR-amplified products were cloned with a TA cloning kit (Invitrogen, San Diego, CA) and se-
quenced as previously described.3 Two clones from each of the human samples were randomly selected and purified using a 
S.N.A.P. miniprep kit (Invitrogen). An Applied Biosysterns (Foster City, CA) automated sequencer model 373A, version 1.2.0, 
was used to derive the DNA sequences, which were then aligned using the GCG package, version 7.0, and manipulated by hand. 
Phylogenies were done using 100 bootstrap replicates in generating unrooted consensus trees with PHYLIP version 3.5p. Dis-
tances were calculated with Kimura's two-parameter method (GCG Package version 7.0). Nucleotide sequences have been sub-
mitted to GenBank and are available under accession numbers AF062309, AF06231O, and AF0623 1 1. 
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either active infection of human tissues or simply the migration 
of SFV-infected baboon cells into those tissue compartments. 
Primers to the mitochondrial cytochrome oxidase subunit II 
(COIl) gene were used to detect baboon-specific genes in the 
xenograft and patient samples.1O In addition, we attempted to 
amplify BaEV DNA. While endogenous viruses do not typi-
cally replicate in their natural host, infection in the transplant 
recipients may also result from either active infection or circu-
lating baboon cells. A summary of these results is presented in 
Table 1. Mitochondrial DNA and BaEV were detected in every 
sample in which SFV was seen. In addition, baboon mito-
chondrial DNA was also detected in liver from both patients at 
early time points and in the lymph node (day 11) from patient 
1 in the absence of detectable SFV. Baboon cells contain both 
BaEV and mitochondrial DNA at high copy number, while SFV 
infection is generally more limited in cell type and cQPY num-
ber. Consequently, our inability to amplify SFV DNA in some 
tissue samples that have evidence of baboon DNA may have 
resulted from these differences and possibly differences in sen-
sitivity of the assays. 
Early reports suggested widespread foamy virus infection in 
humans; however, more recent studies have shown that the hu-
man foamy virus (HFV) is not endemic in human populations. I I 
Our previous studies have shown that baboons harbor host-spe-
cific viruses, based on the genetic relatedness of both SFV pol 
and LTR sequences.3 To determine ifthe foamy virus DNA de-
tected in these patients is of baboon origin and not due to prior 
infection with an HFV, PCR-amplified FV DNA from patient 
2 on day 27 was sequenced. Viral DNA from both liver and 
lymph node of patient 2 was found to be most closely related 
toSFV-Bab viruses (Fig. 3). The phylogenetic tree shows that 
the SFV sequences (SFV-hu2) clustered with the SFV-Bab 
group of viruses and away from other simian and human SFV-
like sequences. To rule out possible contamination of samples, 
PCR amplification and DNA sequencing were repeated with 
the liver sample stored in another laboratory and thus unlikely 
to be contaminated with SFV. Greater than 99% homology be-
tween liver samples was noted (not shown). 
These findings demonstrate the potential for both exogenous 
and endogenous viruses to reside in human recipients of ani-
mal organs for a significant period after transplantation. It is 
possible that these circulating xenogeneic cells could also act 
as conduits for new human infections. Although attempts to iso-
late SFV from these patients was unsuccessful, it remains to be 
determined if SFV is expressed in these recipients (M.G. 
Michaels, unpublished data, 1997). Studies of SFV-infected an-
imal workers would suggest that SFV might replicate in hu-
mans yet, to date, there has been no evidence of retrovirus-re-
lated diseases. It must be emphasized that treatment of 
transplant recipients with immunosuppressive agents could en-
hance the risks from xenogeneic infections. Since retroviruses 
commonly exist as persistent latent infections, with an incidence 
of disease that varies because of both host and viral factors, the 
possibility that baboon foamy viruses might cause disease in 
humans remains a consideration in discussing future animal 
sources for xenotransplantation. Theoretically, other yet to be 
characterized viruses carried by baboons might also be trans-
mitted to human recipients. In addition to baboons, pigs are also 
being considered as donors for human transplantation, and stud-
ies raise the possibility that porcine viruses may be of public 
health significance to humans. 12 Further studies are warranted 
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that closely define the range of infectious agents present in 
donor species, and the potential for these agents to be trans-
mitted to recipients and thus the population at large. 
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